We will engage the course participants in an interactive learning about key aspects of pharmacoepidemiology from a point of view of a regulator. Specific attention will be given to uniqueness of the state of the science in drugs-, devices- and biologics- epidemiology including current differences/potential for convergence in the international regulatory setting. The session is constructed as a dynamic combination of a didactic and a hands-on work on case examples in order to maximize the learnings, knowledge retention and networking among participants.
Dr. Marinac-Dabic will discuss the medical device epidemiology and its role throughout the entire device lifecycle, use of Real-World Evidence (RWE) in regulatory decision making, development of the US National Evaluation System for health Technology (NEST Active Surveillance and NEST Market Place Programs), methodological intersection between epidemiology and data science, and the role of digital health tools in modernizing device surveillance efforts. Dr Dal Pan will focus on understanding the benefit-risk in regulatory context, types of evidentiary standards used in drug regulation and what role pharmacoepidemiologists play in such determination. Dr. Donegan will focus on the challenges in the current pharmacoepidemiology, regulatory epidemiology post COVID-19 pandemics and the global regulatory intersections. The faculty will also discuss the role pharmacoepidemiology plays in regulatory determinations globally, including the opportunities for epidemiologists in the context of recent regulatory convergence and reliance efforts. Following the didactic part of the course the participants will engage interactively in a series of test cases facilitated by the faculty. Finally, the participants will be given opportunity to shape up the next year course by sharing their ideas about the content and desired format.
